# ARQ761 + PARP Inhibitor in Refractory Solid Tumors

> **NCT03575078** · PHASE1 · WITHDRAWN · sponsor: **University of Texas Southwestern Medical Center**

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** ARQ761, Olaparib

## Key facts

- **NCT ID:** NCT03575078
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-06-25
- **Primary completion:** 2019-05-15
- **Final completion:** 2019-05-15
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Project Never Initiated - no human subjects were enrolled and no data regarding humans was collected or studied
- **Last updated:** 2019-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03575078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03575078, "ARQ761 + PARP Inhibitor in Refractory Solid Tumors". Retrieved via AI Analytics 2026-09-05 from https://api.ai-analytics.org/clinical/NCT03575078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*